Abstract Library

#4551 Characterisation and management of neuroendocrine tumours: Findings from a prospective study in Algeria

Introduction: Gastrointestinal neuroendocrine tumours are characterised by varied clinical presentations and behaviours. Their increasing incidence highlights the need for better understanding and management strategies.

Conference:

Presenting Author:

Authors: Zerrouk D, Boukerzaza I, Laouar N, Kassama Z, Mansouri F,

Keywords: Neuroendocrine neoplasm, Observational Study, Treatment Outcomes,

#4549 Alpha-Fetoprotein as a valuable biomarker in neuroendocrine tumours

Introduction: Neuroendocrine tumours (NETs) are a rare group of tumours that pose a significant diagnostic, therapeutic, and prognostic challenge. This complexity arises from the diversity and heterogeneity of these neoplasms, as well as from the limitations of commonly used biomarkers in clinical practice. Alpha-fetoprotein (AFP) is a fetal protein widely used primarily for congenital defects in prenatal diagnostics and in certain malignancies in adults.

Conference:

Presenting Author:

Authors: Musiałkiewicz J, Gut P, Komarnicki P, Maciejewski A, Ruchała M,

Keywords: alpha-fetoprotein, biomarker, neuroendocrine tumour,

#4448 Statins and somatostatin analogues in gastroenteropancreatic neuroendocrine tumours (GEP-NET): Impact on overall survival

Introduction: Gastroenteropancreatic neuroendocrine tumours (GEP-NET) are rare neoplasia with unclear risk factor influencing their development and survival. Statins appear to enhance antiproliferative effect of some chemotherapies in other cancers, but their effect in GEP-NET treated with somatostatin analogues (SSA) are largely unknown.

Conference:

Presenting Author: Benevento E

Authors: Benevento E, Liccardi A, Minotta R, Cannavale G, Di Iasi G,

Keywords: statins, neuroendocrine tumour, gastroenteropancreatic, overall survival, somatostatin analogue,

#4432 Prostatic small cells carcinoma: A case report

Introduction: Small cells prostate carcinoma is a rare entity with bad prognosis. It can be pure, diagnosed denovo, or mixed with adenocarcinoma. Platinum based chemotherapy remains the main therapeutic arm.

Conference:

Presenting Author:

Authors: Boukerzaza I, Zerrouk D, Laouar N, Filali T,

Keywords: prostate, small cell, carcinoma, chemotherapy,

#4357 Proof of concept and design of an externally controlled trial for patients with gastroenteropancreatic neuroendocrine carcinomas based on the randomised phase II BEVANEC trial

Introduction: Neuroendocrine carcinomas of digestive or unknown primary trials are challenging to perform because of disease rarity. BEVANEC trial randomised 126 patients to FOLFIRI +/- bevacizumab in second line, over 5 years, and reported similar overall survival (OS) in both arms.

Conference:

Presenting Author: Hadoux J

Authors: Ganame S, Walter T, Durand A, Lièvre A, Tougeron D,

Keywords: Neuroendocrine carcinoma, synthetic control arm, external control arm, new clinical trial design, randomisation algorithm, real-world data, invers probability weighting,